Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy. METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. The primary efficacy end point was the percentage change in calculated LDL cholesterol level from baseline to week 24. RESULTS: At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was -62 percentage points (P<0.001); the treatment effect remained consistent over a period of 78 weeks. The alirocumab group, as compared with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs. 0.5%), and ophthalmologic events (2.9% vs. 1.9%). In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 to 0.90; nominal P=0.02). CONCLUSIONS: Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY LONG TERM ClinicalTrials.gov number, NCT01507831.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“alirocumab, a PCSK9 monoclonal antibody in clinical use (Robinson et al., 2015)”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Robinson et al., 2015
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Data from the GLAGOV, ODYSSEY COMBO I and ODYSSEY LONG TERM trials show greater efficacy of PCSK9 inhibitors in patients with prior CVD (or myocardial infarction) in terms of LDL-C and percent atheroma volume [86–88].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [88]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [270]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Items 301–400 of 1,019
Ezetimibe: an update on its clinical usefulness in specific patient groups
Hammersley, D. J., & Signy, M. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622316672544 · Cited by 83
“Early trials into PCSK9 inhibitors are encouraging, demonstrating significant LDL-C reductions in patients with primary hypercholesterolaemia compared with placebo and a reduction in early major cardiovascular events [Robinson et al. 2015].”
Schreiber, S. L. (2018) · Israel Journal of Chemistry · doi:10.1002/ijch.201800113 · Cited by 80
Role of PCSK9 in lipid metabolism and atherosclerosis
Lin, X., Xiao, L., Tang, Z., Jiang, Z., & Liu, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.024 · Cited by 84
Navarese, E. P., Kołodziejczak, M., Kereiakes, D. J., Tantry, U. S., O'Connor, C., & Gurbel, P. A. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2994 · Cited by 77
“The reduction in myocardial infarction seen in a recent meta-analysis and in higher-risk patients enrolled in the ODYSSEY LONG TERM (Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy) trial support…”
BackgroundLi, C., Lin, L., Zhang, W., Zhou, L., Wang, H., Luo, X., Luo, H., Cai, Y., & Zeng, C. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.001937 · Cited by 77
Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
Hopewell, J. C., Malik, R., Valdés-Márquez, E., Worrall, B. B., Collins, R., & METASTROKE Collaboration of the ISGC (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx373 · Cited by 74
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Luquero, A., Badimón, L., & Borrell-Pagés, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.639727 · Cited by 80
“They were tested in the OSLER trial (21) and in the ODYSSEY LONG TERM trial (22), respectively (Table 1).”
MethodHobbs, F. R., Banach, M., Mikhailidis, D. P., Malhotra, A., & Capewell, S. (2016) · BMC Medicine · doi:10.1186/s12916-016-0550-5 · Cited by 76
“Safety of the very low concentrations of LDL-C was also confirmed in the ODYSSEY LONG TERM trial with alirocumab added to statins, where no differences in AEs between the group with LDL-C below and over 25 mg/dl were noted [12, 13].”
ResultQuantification of Lipid-Rich Core in Carotid Atherosclerosis Using Magnetic Resonance T2 Mapping
Chai, J. T., Biasiolli, L., Li, L., Alkhalil, M., Galassi, F., Darby, C., Halliday, A. W., Hands, L. J., Magee, T. R., Perkins, J. M., et al. (2016) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2016.06.013 · Cited by 81
Toth, P. P., Descamps, O. S., Genest, J. J., Sattar, N. A., Preiss, D., Dent, R. E., Djedjos, C. S., Wu, Y., Geller, M. L., Uhart, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025233 · Cited by 77
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors
Preiss, D., Tobert, J. A., Hovingh, G. K., & Reith, C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.072 · Cited by 75
New Therapeutic Approaches to the Treatment of Dyslipidemia
Rader, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.005 · Cited by 78
“…for causality of LDL in CVD, the strong human genetics regarding PCSK9 and CHD, and the preliminary data suggesting a reduction in CV events (Robinson et al., 2015; Sabatine et al., 2015), the strong expectation is that PCSK9 inhibition will be proven to reduce CV events (Everett et al.,…”
BackgroundVisconti, L., Benvenga, S., Lacquaniti, A., Cernaro, V., Bruzzese, A., Conti, G., Buemi, M., & Santoro, D. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.08.002 · Cited by 82
“Alirocumab [65] PCSK9 inhibitor 2341 Patients with high cardiovascular risk and LDL > 70 mg/dl 150 mg/2 weeks 2 62% 3”
BackgroundPCSK9 signaling pathways and their potential importance in clinical practice
Wiciński, M., Żak, J., Malinowski, B., Popek, G., & Grześk, G. (2017) · The EPMA Journal · doi:10.1007/s13167-017-0106-6 · Cited by 80
PCSK9: Regulation and Target for Drug Development for Dyslipidemia
Burke, A. C., Dron, J. S., Hegele, R. A., & Huff, M. W. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104944 · Cited by 74
“It remains to be determined if PCSK9 regulates CD36 in humans, although clinical studies using PCSK9 inhibitors have not reported altered liver function or adiposity (35, 36).”
Khan, A. R., Bavishi, C., Riaz, H., Farid, T., Khan, S., Atlas, M., Hirsch, G. A., Ikram, S., & Bolli, R. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003153 · Cited by 78
Cardiovascular Protection in People With Diabetes
Stone, J. A., Houlden, R. L., Lin, P., Udell, J. A., & Verma, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.024 · Cited by 83
Xu, W., Zhang, S., Qin, H., & Yao, K. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05957-3 · Cited by 84
Xie, W., Liu, J., Wang, W., Wang, M., Qi, Y., Zhao, F., Sun, J., Liu, J., Li, Y., & Zhao, D. H. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.103 · Cited by 76
Leibowitz, M., Karpati, T., Cohen-Stavi, C. J., Feldman, B., Hoshen, M., Bitterman, H., Suissa, S., & Balicer, R. D. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2751 · Cited by 74
Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes
Gan, E. S., Tan, H. C., Le, D. H. T., Huynh, T. T., Wills, B., Seidah, N. G., Ooi, E. E., & Yacoub, S. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137536 · Cited by 70
“Two anti-PCSK9 mAbs, alirocumab (Praluent, Sanofi/Regeneron Pharmaceuticals) (34, 44) and evolucumab (Repatha, Amgen) (45, 46), have been licensed as treatments to lower plasma cholesterol.”
BackgroundMethodLow-Density Lipoprotein Cholesterol and Alzheimer's Disease: A Systematic Review and Meta-Analysis
Zhou, Z., Liang, Y., Zhang, X., Xu, J., Lin, J., Zhang, R., Kang, K., Liu, C., Zhao, C., & Zhao, M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00005 · Cited by 82
Application of targeted therapy strategies with nanomedicine delivery for atherosclerosis
Ou, L.-C., Zhong, S., Ou, J., & Tian, J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0436-0 · Cited by 76
Recent Update on siRNA Therapeutics
Ebenezer, O., Oyebamiji, A. K., Olanlokun, J. O., Tuszyński, J. A., & Wong, G. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083456 · Cited by 78
“%) in LDL cholesterol levels; this decrease is comparable to that achieved with PCSK9-targeting monoclonal antibodies [174,175].”
Masana, L., Girona, J., Ibarretxe, D., Rodríguez‐Calvo, R., Rosales, R., Vallvé, J.-C., Rodríguez-Borjabad, C., Guardiola, M., Rodríguez, M. M., Guaita‐Esteruelas, S., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.12.018 · Cited by 75
Drexel, H., Coats, A. J. S., Spoletini, I., Bilato, C., Mollace, V., Filardi, P. P., & Rosano, G. M. C. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz079 · Cited by 75
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 76
Cholesterol metabolism related genes in osteoarthritis
Papathanasiou, I. V., Anastasopoulou, L., & Tsezou, A. (2021) · Bone · doi:10.1016/j.bone.2021.116076 · Cited by 72
Wang, X., Wen, D., Chen, Y., Ma, L., & You, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01542-4 · Cited by 67
Wilkinson, M. J., Lepor, N. E., & Michos, E. D. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028892 · Cited by 77
Self-citationPeikert, A., Kaier, K., Merz, J., Manhart, L., Schäfer, I., Hilgendorf, I., Hehn, P., Wolf, D., Willecke, F., Sheng, X., et al. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01511-0 · Cited by 73
Khan, S. U., Rahman, H., Okunrintemi, V., Riaz, H., Khan, M. S., Sattur, S., Kaluski, E., Lincoff, A. M., Martin, S. S., & Blaha, M. J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011581 · Cited by 70
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.019 · Cited by 70
The Labor Market for Health Workers in Africa
Soucat, A. L. B., & Scheffler, R. M. (2013) · World Bank, Washington, DC eBooks · doi:10.1596/978-0-8213-9555-4 · Cited by 70
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
Bardolia, C., Amin, N. S., & Turgeon, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.789931 · Cited by 74
“To date, no clinical trials have demonstrated an increase rate of diabetes with PCSK9 inhibitor use (11, 56, 57).”
BackgroundAbu‐Assi, E., López-López, A., Salvado, V. G., Diéguez, A. R., Peña, C., Bouzas‐Cruz, N., Raposeiras‐Roubín, S., Abumuaileq, R. R.-Y., García‐Acuña, J. M., & González‐Juanatey, J. R. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.06.015 · Cited by 74
Bile acids at the cross-roads of gut microbiome–host cardiometabolic interactions
Ryan, P. M., Stanton, C., & Caplice, N. M. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0299-9 · Cited by 71
Tuñón, J., Bäck, M., Badimón, L., Bochaton‐Piallat, M., Cariou, B., Daemen, M. J. A. P., Egido, J., Evans, P. C., Francis, S., Ketelhuth, D. F. J., et al. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318773384 · Cited by 75
Self-citationRay, K. K., Vallejo-Vaz, A. J., Ginsberg, H. N., Davidson, M. H., Louie, M. J., Bujas-Bobanovic, M., Minini, P., Eckel, R. H., & Cannon, C. P. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.06.896 · Cited by 69
Nonstatin Therapies for Management of Dyslipidemia: A Review
Sando, K. R., & Knight, M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.001 · Cited by 73
“The Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy (ODYSSEY LONG TERM) trial included 2341 patients at high risk for CVD who received statins at maximum tolerated doses.(137) A post hoc analysis…”
BackgroundCurrent and future trends in the lipid lowering therapy
Okopień, B., Bułdak, Ł., & Bołdys, A. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.03.016 · Cited by 72
Standl, E., Schnell, O., McGuire, D. K., Ceriello, A., & Rydén, L. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30033-5 · Cited by 73
The relationship between Lp(a) and CVD outcomes: a systematic review
Forbes, C. A., Quek, R. G. W., Deshpande, S., Worthy, G., Wolff, R. F., Stirk, L., Kleijnen, J., Gandra, S. R., Djedjos, S., & Wong, N. D. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0258-8 · Cited by 72
“as apheresis [95, 99], antisense therapy which targets Apo(a) [100] and PCSK9 inhibitors [10, 101, 102] could provide additional benefit in the treatment of patients at risk of CVD beyond LDL-C lowering [18], and evidence of such additional benefit beyond LDL-C lowering should be investigated further in ongoing and fu…”
BackgroundLong-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system
Momtazi‐Borojeni, A. A., Jaafari, M. R., Badiee, A., & Sahebkar, A. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.02.001 · Cited by 70
Microvesicles in Autoimmune Diseases
Liu, M., Williams, K. J., & Werth, V. P. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.06.005 · Cited by 74
Intensive LDL-cholesterol lowering therapy and neurocognitive function
Banach, M., Rizzo, M., Nikolić, D., Howard, G., Howard, V. J., & Mikhailidis (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.001 · Cited by 68
Lipid lowering agents of natural origin: An account of some promising chemotypes
Singh, S. P., & Sashidhara, K. V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.020 · Cited by 70
Khan, S. U., Khan, M. U., Valavoor, S., Khan, M. S., Okunrintemi, V., Mamas, M. A., Leucker, T. M., Blaha, M. J., & Michos, E. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871733 · Cited by 67
Adorni, M. P., Ruscica, M., Ferri, N., Bernini, F., & Zimetti, F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00120 · Cited by 67
Kastelein, J. J. P., Hovingh, G. K., Langslet, G., Baccara-Dinet, M. T., Gipe, D. A., Chaudhari, U., Zhao, J., Minini, P., & Farnier, M. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.12.004 · Cited by 67
“The PCSK9 inhibitor alirocumab has been demonstrated to result in significant LDL-C reductions, both as monotherapy and on background statin therapy, in a variety of patient populations across the Phase 3 ODYSSEY clinical trial programme.(8-19) The current analysis aimed to determine the LDL-C-lowering efficacy and sa…”
BackgroundResultSelf-citationCost-Effectiveness of Alirocumab
Kazi, D. S., Penko, J. M., Coxson, P. G., Guzman, D., Wei, P. C., & Bibbins-Domingo, K. B. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1776 · Cited by 67
Vlachopoulos, C. V., Terentes-Printzios, D. G., Georgiopoulos, G. A., Skoumas, I., Koutagiar, I. P., Ioakeimidis, N., Stefanadis, C., & Tousoulis, D. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.922 · Cited by 69
Genetic-Driven Druggable Target Identification and Validation
Floris, M., Olla, S., Schlessinger, D., & Cucca, F. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.04.004 · Cited by 73
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
Chapman, M. J., Stock, J. K., & Ginsberg, H. N. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000239 · Cited by 73
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Raschi, E., Casula, M., Cicero, A. F. G., Corsini, A., Borghi, C., & Catapano, A. L. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108507 · Cited by 71
Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes
Nowak, C., Carlsson, A. C., Östgren, C. J., Nyström, F. H., Alam, M., Feldreich, T., Sundström, J., Carrero, J. J., Leppert, J., Hedberg, P., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4641-z · Cited by 66
Effects of immunization against PCSK9 in an experimental model of breast cancer
Momtazi‐Borojeni, A. A., Nik, M. E., Jaafari, M. R., Banach, M., & Sahebkar, A. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.84734 · Cited by 67
“The famous FDA-approved monoclonal antibodies (mAbs) alirocumab [31, 32] and evolocumab [33, 34] are currently the most effective PCSK9 inhibitors on the market for reducing plasma LDL-C in patients with hypercholesterolemia.”
BackgroundGuedeney, P., Sorrentino, S., Giustino, G., Chapelle, C., Laporte, S., Claessen, B. E. P. M., Ollier, É., Camaj, A., Kalkman, D. N., Vogel, B., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa024 · Cited by 67
Statin Treatment in Patients With Intracerebral Hemorrhage
Endres, M., Nolte, C. H., & Scheitz, J. F. (2017) · Stroke · doi:10.1161/strokeaha.117.019322 · Cited by 70
Robinson, J. G., & Stone, N. J. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv182 · Cited by 70
“Preliminary data from post hoc analyses of Phase III efficacy/safety RCTs suggest PCSK-9 monoclonal antibodies may further reduce ASCVD risk when added to statin therapy.(35,36) Depending on the RRRs observed in the ongoing ASCVD outcomes RCTs, the NNTs may be quite acceptable across a wide range of ASCVD absolute ris…”
Self-citationGiugliano, R. P., Mach, F., Zavitz, K. H., Kurtz, C. E., Schneider, J., Wang, H., KEECH, A. C., Pedersen, T. R., Sabatine, M. S., Sever, P. S., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22678 · Cited by 65
Inclisiran: a new generation of lipid-lowering siRNA therapeutic
Zhang, Y., Chen, H., Hong, L., Wang, H., Li, B., Zhang, M., Li, J., Liu, Y., & Liu, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1260921 · Cited by 74
HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target
Bhatt, A. B., & Rohatgi, A. K. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0554-1 · Cited by 73
PCSK9 and diabetes: is there a link?
Momtazi‐Borojeni, A. A., Banach, M., Pirro, M., Stein, E. A., & Sahebkar, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.006 · Cited by 65
Pećin, I., Hartgers, M. L., Hovingh, G. K., Dent, R. E., & Reiner, Ž. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317717346 · Cited by 70
“Term trial of alirocumab, 2341 patients at high risk of ASCVD, of whom 18%hadHeFH, received alirocumab 150mg every 2 weeks for 78 weeks.(134) In a post hoc analysis, the rate of MACEs was lower for patients receiving alirocumab than for those receiving placebo (1.”
BackgroundNishikido, T., & Ray, K. K. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00199 · Cited by 70
“References (51, 52) (67) (74, 75) (90, 91) (107–112) (119, 120) (122–124)”
Swiger, K. J., & Martin, S. S. (2015) · Drug Safety · doi:10.1007/s40264-015-0296-6 · Cited by 66
“More recent data from the OSLER program supports the earlier findings [52].”
ResultBlom, D. J., Koren, M. J., Roth, E. M., Monsalvo, M. L., Djedjos, C. S., Nelson, P., Elliott, M., Wasserman, S. M., Ballantyne, C. M., & Holman, R. R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12788 · Cited by 66
Self-citationGrześk, G., Dorota, B., Wołowiec, Ł., Wołowiec, A., Osiak, J., Kozakiewicz, M., & Banach, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113957 · Cited by 58
Ferri, N., Corsini, A., Macchi, C., Magni, P., & Ruscica, M. (2015) · Translational research · doi:10.1016/j.trsl.2015.10.004 · Cited by 70
“In the ODYSSEY LONG TERM trial, the effect of alirocumab was assessed in patients at high risk for cardiovascular events who had LDL-C levels of 70 mg/dL or more and were receiving treatment with statins at the maximum tolerated dose.(88) The administration of alirocumab at the dose of 150 mg every 2 weeks determined…”
MethodHegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
Self-citationManagement of Familial Hypercholesterolemia: Current Status and Future Perspectives
Lui, D. T. W., Lee, A. C. H., & Tan, K. C. B. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa122 · Cited by 68
Farmakis, I. T., Doundoulakis, I., Pagiantza, A., Zafeiropoulos, S., Antza, C., Karvounis, H. I., & Giannakoulas, G. A. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000963 · Cited by 65
Forbang, N. I., Criqui, M. H., Allison, M., Ix, J. H., Steffen, B. T., Cushman, M., & Tsai, M. Y. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.08.114 · Cited by 63
“Lp(a), mg/dL 18 [8-40] 4 [2-6] 12 [10-15] 26 [22-32] 67 [51-89] Age, years 62 6 10 62 6 11 62 6 10 62 6 10 62 6 10 Male sex 2217 (48) 600 (51) 546 (48) 577 (50) 484 (42) Ethnicity EA 1685 (36) 572 (49) 459 (40) 336 (29) 318 (28) AA 1327 (29) 101 (9) 184 (16) 465 (40) 576 (50) HA 1052 (23) 345 (29) 299 (26) 224 (19) 18…”
Chan, D. C., Pang, J., McQuillan, B., Hung, J., Beilby, J. P., Barrett, P. H. R., & Watts, G. F. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.10.017 · Cited by 68
“However, two recent clinical trials support the role of PCSK9 on atherosclerosis showing about 50% relative reductions in cardiovascular events with PCSK9 inhibition over 12-18 months in a range of patient populations [19,20].”
BackgroundUnderstanding PCSK9 and anti-PCSK9 therapies
McKenney, J. M. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.01.001 · Cited by 66
Ridker, P. M., Amarenco, P., Brunell, R., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Köenig, W., Nissen, S. E., Revkin, J. H., Santos, R. D., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.05.010 · Cited by 65
Self-citationFarnier, M., Gaudet, D., Valcheva, V., Minini, P., Miller, K., & Cariou, B. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.08.273 · Cited by 63
Self-citationFaludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 107
Zheng, J., Wang, J., Zhang, Y., Xia, J., Guo, H., Hu, H., Shan, P., & Li, T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.891929 · Cited by 70
Akbari, P., Sosina, O. A., Bovijn, J., Landheer, K., Nielsen, J. B., Kim, M., Aykul, S., De, T., Haas, M. E., Hindy, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32398-7 · Cited by 65
A robust cis-Mendelian randomization method with application to drug target discovery
Lin, Z., & Pan, W. (2024) · Nature Communications · doi:10.1038/s41467-024-50385-y · Cited by 70
Abtan, J., Bhatt, D. L., Elbez, Y., Sorbets, E., Eagle, K. A., Ikeda, Y., Wu, D., Hanson, M. E., Hannachi, H., Singhal, P. K., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22583 · Cited by 66
PCSK9 inhibitors in clinical practice: Delivering on the promise?
Stoekenbroek, R. M., Hartgers, M. L., Rutte, R., de Wijer, D. D., Stroes, E. S. G., & Hovingh, G. K. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.11.027 · Cited by 72
Self-citationCannabinoids, the Heart of the Matter
Alfulaij, N., Meiners, F., Michalek, J., Small-Howard, A. L., Turner, H. C., & Stokes, A. J. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009099 · Cited by 67
“The human monoclonal antibody, alirocumab, inhibiting proprotein convertase subtilisin-kexin type 9 (PCSK9), was found to decrease LDL levels in patients by 62% when added to a statin therapy.(30) Ischemic preconditioning uses the transient induction of”
BackgroundFeng, Q., Wei, W., Chaugai, S., Leon, B. G. C., Mosley, J. D., Leon, D. A. C., Jiang, L., Ihegword, A., Shaffer, C. M., Linton, M. F., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.7223 · Cited by 62
Balla, S., Ekpo, E., Wilemon, K. A., Knowles, J. W., & Rodríguez, F. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00881-5 · Cited by 65
Cao, Y., Liu, H., Dong, Q., Li, S., & Li, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13235 · Cited by 61
Khan, S. U., Talluri, S., Riaz, H., Rahman, H., Nasir, F., Bin Riaz, I., Sattur, S., Ahmed, H., Kaluski, E., & Krasuski, R. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318766612 · Cited by 61
Lipid Testing and Statin Dosing After Acute Myocardial Infarction
Wang, W. T., Hellkamp, A. S., Doll, J. A., Thomas, L. E., Návar, A. M., Fonarow, G. C., Julien, H. M., Peterson, E. D., & Wang, T. Y. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.006460 · Cited by 64
Cholesterol-Lowering Agents: PCSK9 Inhibitors Today and Tomorrow
Rosenson, R. S., Hegele, R. A., & Köenig, W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313238 · Cited by 63
Zeitlinger, M., Bauer, M., Reindl-Schwaighofer, R., Stoekenbroek, R. M., Lambert, G., Berger-Sieczkowski, E., Lagler, H., Oesterreicher, Z., Wulkersdorfer, B., Lührs, P., et al. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03149-2 · Cited by 57
Arsenault, B. J., Petrides, F., Tabet, F., Bao, W., Hovingh, G. K., Boekholdt, S. M., Ramin‐Mangata, S., Meilhac, O., DeMicco, D. A., Rye, K., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.001 · Cited by 61
Self-citationKoh, K. K., Nam, C., Chao, T., Liu, M.-E., Wu, C.-J., Kim, D., Kim, C. J., Li, I., Li, J., Baccara‐Dinet, M. T., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.09.007 · Cited by 62
“52).(16) The ODYSSEY OUTCOMES study of more than 18,000 patients will be completed by the end of 2017 and will report efficacy on CV events as well as long-term safety data.”
Rao, A. S., Lindholm, D., Rivas, M. A., Knowles, J. W., Montgomery, S. B., & Ingelsson, E. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002162 · Cited by 60
Farnier, M., Hovingh, G. K., Langslet, G., Dufour, R., Baccara‐Dinet, M. T., Din-Bell, C., Manvelian, G. Z., & Guyton, J. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.036 · Cited by 62
Self-citationOuweneel, A. B., & Eck, M. V. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.10.009 · Cited by 62
Statin Intolerance: the Clinician’s Perspective
Štulc, T., Češka, R., & Gotto, A. M. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0552-3 · Cited by 64
“Meta-analyses of phase 2 and 3 trials demonstrated a >50 % reduction of cardiovascular events with evolocumab and alirocumab [31, 32], and the results of major clinical trials are eagerly awaited by Curr Atheroscler Rep (2015) 17: 69 Page 5 of 7 69”
Triglycerides and residual risk
Vallejo‐Vaz, A. J., Corral, P., Schreier, L. E., & Ray, K. K. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000530 · Cited by 65
“PCSK9 inhibitors have shown to significantly reduce not only LDL-C but also non-HDL-C, apoB and triglycerides as well as increasing HDL-C and apolipoprotein A-I, in both diabetic and nondiabetic patients [31,32].”
BackgroundBruckert, E., Parhofer, K. G., Gonzalez-Juanatey, J. R., Nordestgaard, B., Arca, M., Giovas, P., & Ray, K. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01285-2 · Cited by 59
Metadata
- Authors
- Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., Koren, M. J., Lepor, N. E., Lorenzato, C., Pordy, R., Chaudhari, U., & Kastelein, J. J. P.
- Affiliations
- University of Iowa (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- Université de Lille (FR)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Oslo University Hospital (NO)
- University of the Witwatersrand (ZA)
- Jacksonville Center for Clinical Research (US)
- Westside Medical Associates of Los Angeles (US)
- Sanofi (France) (FR)
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1489-1499
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2001328643
- Semantic Scholar
- 942bcfdc93b04ccb90a2d3e1df4c7950a45e92c2
- Cited by
- 2,296
- References
- 35
- Citations by year
- 2026: 67 · 2025: 103 · 2024: 150 · 2023: 141 · 2022: 134 · 2021: 159 · 2020: 165 · 2019: 226 · 2018: 251 · 2017: 339 · 2016: 369 · 2015: 183
- FWCI
- 383.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- alirocumab, PCSK9 inhibition, LDL cholesterol lowering, statin therapy, major adverse cardiovascular events, cardiovascular risk reduction, monoclonal antibodies, injection site reactions, high-risk patients, lipid-lowering therapy
- MeSH terms
- Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.